Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Invested Capital (2016 - 2025)

Historic Invested Capital for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $950.2 million.

  • Ligand Pharmaceuticals' Invested Capital rose 1295.72% to $950.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $950.2 million, marking a year-over-year increase of 1295.72%. This contributed to the annual value of $830.5 million for FY2024, which is 1848.56% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Invested Capital of $950.2 million as of Q3 2025, which was up 1295.72% from $828.5 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Invested Capital high stood at $950.2 million for Q3 2025, and its period low was $597.5 million during Q4 2022.
  • Its 5-year average for Invested Capital is $786.9 million, with a median of $795.5 million in 2025.
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 2751.95% in 2023, then surged by 2594.45% in 2024.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Invested Capital stood at $821.3 million in 2021, then dropped by 27.24% to $597.5 million in 2022, then grew by 17.31% to $700.9 million in 2023, then grew by 18.49% to $830.5 million in 2024, then increased by 14.41% to $950.2 million in 2025.
  • Its Invested Capital stands at $950.2 million for Q3 2025, versus $828.5 million for Q2 2025 and $795.5 million for Q1 2025.